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The aim of this study was to provide a better insight into breast cancer response to chemotherapy. Chemotherapy im-
proves outcome in breast cancer patients. The effect of cytotoxic treatment cannot be predicted for individual patients. Therefore,
the identification of tumour characteristics associated with tumour response and outcome is of great clinical interest. We studied
97 patients, who received anthracycline-based neoadjuvant chemotherapy. Tumour samples were taken prior to and
after chemotherapy. We quantified the response to chemotherapy clinically and pathologically and determined histological and
molecular tumour characteristics. We assessed changes in the expression of Bcl-2, ER, P53 HER2 and Ki-67. Association
with response and outcome was tested for all parameters. The experimental results showed 15 clinical (17%) and three
(3%) pathological complete remissions. There were 18 (20%) clinical vs 29 (33%) pathological nonresponders. The expression of
most markers was similar before and after chemotherapy. Only Ki-67 was significantly decreased after chemotherapy.
Factors correlated with response were: large tumour size, ER negativity, high Ki-67 count and positive P53 status.
Tumour response and marker expression did not predict disease-free or overall survival. In conclusion, clinical and pathological
response assessments are poorly associated. Proliferation decreases significantly after chemotherapy. ER negativity and a high
proliferation index are associated with better response. HER2 status does not predict response, and outcome is not related to
tumour response.
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The addition of adjuvant chemotherapy to standard breast cancer
therapy has been shown to improve outcome substantially (Early
Breast Cancer Trialists’ Collaborative Group, 1998). There are
several arguments for applying chemotherapy in a so-called
neoadjuvant treatment setting, prior to surgery. First, by down-
staging the tumour, less extensive resections are needed and breast
conservation becomes increasingly feasible (Makris et al, 1998;
Mauriac et al, 1999). Second, micrometastases that may be present
are thus treated at the earliest possible moment. This could prevent
changes in metastatic cells, associated with a worse prognosis: the
acceleration of growth upon resection of the primary tumour
(Gunduz et al, 1979; Fisher et al, 1983) and the development of
drug-resistant subclones (Goldie and Coldman, 1979). A third
advantage of neoadjuvant chemotherapy is that it enables the
monitoring of treatment efficacy and makes it possible to identify
markers of response to chemotherapy.
Most published data on the effect of cytotoxic treatment
in breast cancer have been obtained by comparing the survival
of large groups of patients with or without chemotherapy. A
more direct approach is to measure the primary tumours of
individual patients before and after treatment. Assuming that
the response – that is, decrease of tumour volume – is
representative of the sensitivity of all tumour cells, this could
yield a prognostic tool: a better response could be associated with
an improved outcome.
It has not been demonstrated in what way the effects of
chemotherapy exposure should be measured to obtain a valid
parameter of the response. Whether the response of breast cancer
to chemotherapy actually is a prognostic factor is also not an
established fact. There are many studies investigating the
prognostic factors in breast cancer, such as the expression of
HER2 (reviewed in Hamilton and Piccart, 2000), P53 (reviewed in
Bergh, 1999) and Bcl-2 (reviewed in Daidone et al, 1999). In
addition, there are an increasing number of studies investigating
factors that can predict response to chemotherapy. Histopatho-
logical changes of breast tumours as a result of chemotherapy
exposure have been described in a limited number of papers
(Kennedy et al, 1990; Aktepe et al, 1996; Miller et al, 1997; Gajdos
et al, 2002).
In this study, we have made a comparison of the same set of
tumours before and after exposure to chemotherapy, describing
changes in three aspects: size, histopathologic features, and
expression of molecular markers. We have correlated these factors
with overall (OS) and disease-free survival (DFS) of the patients.
The main aim of this study was to provide a better insight into
breast cancer response to chemotherapy by identifying factors that
can predict response of the primary tumour to neoadjuvant Revised 14 October 2002; accepted 11 November 2002
*Correspondence: Dr MJ van de Vijver, Plesmanlaan 121, 1066 CX
Amsterdam, The Netherlands; E-mail: m.vd.vijver@nki.nl
British Journal of Cancer (2003) 88, 406 – 412
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yanthracycline-based chemotherapy and by assessing the associa-
tion between tumour response and outcome.
MATERIALS AND METHODS
Patients
All patients (n¼97) presented with breast cancer with extensive
axillary lymph node involvement. The diagnosis of breast cancer
was made by clinical, radiological and cytological assessment in
all patients. For those patients with inadequate cytological
aspirates, histological confirmation of the diagnosis was obtained
with primary tumour biopsy. Patients were entered in a single-
institution, randomised trial, studying the effects of high-dose
chemotherapy and haematopoietic progenitor-cell support trans-
plantation. The results of this study were published earlier
(Rodenhuis et al, 1998). In short, the eligibility criteria of this
study were: age under 60 years, level III involvement of axillary
lymph nodes (detected with an infraclavicular histological lymph
node biopsy that was performed in all patients and had to be
tumour-positive to be entered in the trial), absence of distant
metastases and locally resectable disease. Patients received three
courses of cyclophosphamide (500mgm
 2), epirubicin
(120mgm
 2) and 5-fluorouracil (500mgm
 2) (FE120C) once every
3 weeks as up-front neoadjuvant therapy. All but one patient
finished the up-front chemotherapy, and 94% did so within the
planned time frame. Following up-front treatment, patients
underwent definitive surgery, consisting of either a mastectomy
(n¼81) or breast-conserving surgery (n¼16) and axillary lymph
node dissection. After surgery, patients were randomly assigned to
receive conventional chemotherapy alone (one more cycle of
FE120C) or FE120C followed by an additional high-dose course
(cyclophosphamide 6gm
 2, thiotepa 480mgm
 2, carboplatin
1600mgm
 2) and peripheral-blood progenitor-cell support after
the fourth FE120C course. All patients received radiation therapy
and 2 years of tamoxifen upon finishing the respective chemo-
therapy regimens. Written informed consent was obtained from all
patients before enrolment in the study. Patients were again asked
for their permission to participate after neoadjuvant chemotherapy
and surgery and before randomisation.
Histology
The assessable tumours were graded and classified from haema-
toxylin and eosin (H&E)-stained sections of the surgical resection
specimen obtained after chemotherapy treatment. In cases of
(nearly) complete primary tumour remission, the residual axillary
node metastases were used to grade and type the tumour.
Histological classification was done according to the WHO criteria.
Grading was done according to the criteria described by Elston and
Ellis (1991).
Response to FE120C – clinical assessment
Clinical response was categorised according to the UICC criteria
(Hayward et al, 1977). A clinical complete remission (cCR) was
defined as the disappearance of all palpable tumour deposits.
Clinical response was scored as partial remission (cPR) if the
reduction of tumour volume exceeded 50%. Tumour reduction less
than 50% or increase of volume up to 25% was scored as stable
disease (cSD). An increase of more than 25% was designated as
progressive disease.
Response to FE120C – pathological assessment
Histopathological evidence of response was scored in H&E
sections of the surgical specimen. Only invasive carcinomas – of
any subtype – were studied, and the presence or absence of in situ
carcinoma was disregarded. The words tumour and response
are therefore consistently used when referring to invasive
carcinomas. Quantitatively we scored if and where tumour
deposits remained after up-front chemotherapy: at the site of
the primary tumour (diameter) and in the axilla (number of
positive nodes vs total number of retrieved nodes). Qualitatively
we scored morphologic alterations of tumour cells and surround-
ing tissue. From an earlier pilot study, comparing the first
17 patients from this trial group to 17 randomly selected untreated
breast carcinoma control cases (unpublished data of JLP and PLR),
we defined two characteristics associated with chemotherapy
exposure: fibrosis and cytonuclear changes. Fibrosis, resembling
scar tissue, appeared as hyaline-rich, cell-deprived, desmoplastic
stroma and was only scored thus if located at the peripheral
edges of the tumour; central hyalinisation is frequently seen in
untreated tumours. Regressive cytonuclear alterations were scored
if marked anisocytosis, vacuolisation and increase of nuclear size
was seen in residual tumour cells. The few publications addressing
the subject of breast cancer morphology after chemotherapy
essentially describe the same pattern of changes that we found
(Kennedy et al, 1990; Aktepe et al, 1996; Miller et al, 1997; Gajdos
et al, 2002).
A pathological complete remission (pCR) was defined if no
residual carcinoma was seen macroscopically and microscopically.
If minimal tumour residues were found in the breast or the axilla,
this was scored as microscopic residual disease (pMRD). Cases
with histopathological characteristics of chemotherapy exposure –
as described above – but a macroscopic residual tumour mass were
categorised as histopathological changes in a macroscopic residual
tumour mass (pHRTM). All cases, in which no qualitative or
quantitative histopathologic evidence of tumour response was
seen, were scored as no response (pNR).
Immunohistochemistry
For 56 patients, material of the tumour obtained prior to
chemotherapy was available for immunohistochemistry (IHC): a
histological biopsy of the primary tumour (n¼8) or a histological
biopsy of the infraclavicular lymph node (n¼48). For the other
patients what was left of the prechemotherapy biopsy material
after diagnostic work-up was too little to process with IHC. For the
postchemotherapy material the problem of limited quantity was
also met, however to a lesser extent. Of 86 patients the surgical
resection specimen obtained after neoadjuvant chemotherapy was
still available for IHC.
Formalin-fixed paraffin-embedded tissue samples were stained
with antibodies against HER2 (3B5; 1:10000), P53 (DO7; 1:8000;
mouse IgG2b; DAKO, Denmark), oestrogen receptor (ER) (1D5;
1:150; mouse IgG1; DAKO, Denmark), Ki-67 (MIB-1; 1:1000;
mouse IgG1; Immunotech, France) and Bcl-2 (clone 124; 1:100;
mouse IgG1; DAKO, Denmark). Sections of 5mm were deparaffi-
nised in xylol and alcohol, and endogenous peroxidase was
quenched in methanol-peroxide (3%; 200). Slides were pretreated
(antigen retrieval) in citrate buffer (0.01 M citric acid, in distilled
water (pH 6.0); 150 at 1001C), blocked with normal goat serum (5%;
300) and then incubated with the primary antibody, overnight at
41C. Binding of the monoclonal antibody was detected with biotin-
labelled goat anti-mouse IgG (1:200; 300; DAKO, Denmark) and
horseradish peroxidase-labelled avidin – biotin complex (1:100;
300; DAKO, Denmark). Bound peroxidase was developed with 3,30-
diaminobenzidine tetrahydrochloride (Sigma, USA) and 0.02%
H2O2 in PBS. All reagents were diluted in a 1% bovine albumin
solution in PBS. Anti-mouse IgG solution was admixed with 10%
normal human serum to prevent nonspecific binding. Replacement
of the primary antibody with 1% bovine albumin solution in PBS
served as negative control.
IHC results of Bcl-2, ER and P53 were scored semiquantitatively
on a six-point scale for the percentage of positively staining
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ytumour cells (0; 1o10%; 2¼10–25%; 3¼25–50%; 4¼50–75%;
5¼75–100%). Staining patterns recognised as positive were
circumferential membrane-bound staining (HER2), nuclear stain-
ing (ER, Ki-67, P53) or cytoplasm staining (Bcl-2). HER2 was
scored with the system that has recently come to use for clinical
testing (0; 1+¼410% cells weakly positive; 2+¼moderate
homogeneous staining; 3+¼strong homogeneous staining).
Ki-67 (the proliferating fraction) was scored quantitatively by
counting the number of positive tumour cells in a total of 200 per
slide.
Survival
We determined both OS and DFS from the start of neoadjuvant
treatment. End points were death for OS and death or any
recurrence of breast cancer for DFS. The original trial design had
two randomly assigned treatment protocols: a high-dose chemo-
therapy arm and a standard chemotherapy arm, as described
above. Survival comparisons between groups have been published
(Rodenhuis et al, 1998). The outcome was reanalysed after 7 years
of follow-up and was still identical for both treatment groups
(Schrama et al, 2002). For the analysis of predictive factors, we
have therefore used the total patient population regardless of the
treatment arm they were assigned to.
Analysis of results
All data were analysed with SPSS 10.0.7 for Windows.
For correlation between expression levels of markers and response
parameters, we used the two-sided Spearman’s test for nonpara-
metric correlation. For crosstabulation, markers were categorised
dichotomously as positive or negative. The cut-off for Bcl-2,
ER and P53 was at 10% or more tumour cells staining (score 41).
For HER2, 2+ and 3+ were regarded as positive. Ki-67
was dichotomised in low (less than 40 staining nuclei out of 200)
vs high (40 or more staining nuclei out of 200). Differences
of expression levels between paired samples (pre- vs post-
chemotherapy) scored on a six-point scale were assessed
with Wilcoxon’s signed ranks test. Significance of changes in
dichotomised status was tested with McNemar’s test. Response
was dichotomised depending on the way in which it was assessed:
clinically as cCR vs non-cCR and pathologically as any response
(pCR, pMRD or pHRTM) vs no response (pNR). Association
between dichotomised scores of marker expression and tumour
response was tested with the Fisher exact test. Analyses of survival
differences between the patient subgroups were carried out
with the log-rank test. Response scores and marker expression
were also tested for association with outcome in a Cox regression
model.
RESULTS
In tumour samples taken from 97 breast cancer patients with
extensive lymph node involvement, who were preoperatively
treated with three courses of FE120C, response to neoadjuvant
chemotherapy was measured. The association with response and
survival of histopathological features and of a panel of markers
was tested. In addition, we compared marker expression before
and after chemotherapy in the same tumour, and response to
chemotherapy was tested as a possible predictor of outcome.
Response to FE120C
Clinical and pathological response data were available for 89
patients.
Upon three cycles of FE120C, 15 patients (17%) had a clinical
complete remission (cCR), 56 had a partial remission (cPR) (63%)
and 18 had stable disease (SD) (20%). Progressive disease was not
observed.
Histopathologic signs of response were seen in 60 patients
(67%). Three patients had a pCR (3%) and only pMRD was found
in 11 cases (12%). In 46 cases (52%) pHRTM was found. In all, 29
patients (33%) had pNR. Including three patients with a pCR, 15
patients (17%) had no residual tumour in the breast after
neoadjuvant treatment and four (4%) had a tumour-negative
axilla. The mean tumour diameter measured in the surgical sample
after neoadjuvant chemotherapy was 2.6cm (range 0–10cm).
Of the 15 patients with cCR, two (13%) also had a pCR and four
(27%) had pMRD. In nine cCR patients (60%) only pHRTM (n¼7)
or pNR (n¼2) was observed. Of three patients with a pCR, two
were also classified as cCR and one was clinically scored as cPR. In
all, 10 out of 29 pNR cases were clinically scored as cSD (34%), 17
were scored as cPR (59%) and two as cCR (7%). These data are
summarized in Table 1.
Integrated clinical and histopathological definition of
response
The correlation between clinical and pathological response was not
very strong, but highly significant (r¼0.34; P¼0.001). Aiming to
take into account as many parameters as possible to define the
degree of tumour response, we reclassified the patients into seven
categories integrating both clinical and histopathological response
measurement:
Table 1 (A) Histopathological findings in patients with a clinical complete remission and (B) clinical
findings in patients with no histopathological signs of response
(A) Pathological response cCR (n=15) (B) clinical response pNR (n=29)
pCR 2 CCR 2
pMRD 4 cPR 17
pHRTM 7
pNR 2 cSD 10
Any pathological sign of response 13 (87%) Any clinical sign of response 19 (66%)
Histopathological examination: pCR=pathological complete remission; pMRD=minimal residual disease; pHRTM=his-
topathological changes in macroscopic residual tumour mass; pNR=no histopathological signs of response.
Clinical examination: cCR=clinical complete remission; cPR=partial response; cSD=stable disease.
I. Pathological complete remission (pCR; n=3).
II. Microscopic residual disease and clinical complete remission (pMRD and
cCR; n=4).
III. Microscopic residual disease, but no clinical complete remission (pMRD and
cPR/cSD; n=7).
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The mean age of patients at diagnosis was 45 years. A histological
classification could be made for 76 tumours: 49 were classified as
invasive ductal carcinoma (IDC) (64.5%), 11 as invasive lobular
carcinoma (ILC) (14.5%) and 16 as other types (21%), including
mixed invasive patterns. Malignancy grading was possible for 73
tumours: 25 (34%) were grade I, 30 were grade II (41%) and 18
(25%) were grade III.
Expression of markers
IHC was performed with sections from as many pre- and
postchemotherapy histological biopsy samples as were available.
We had 56 prechemotherapy samples:
K primary tumour (n¼8),
K infraclavicular lymph node (n¼48).
We had 86 samples after chemotherapy, all from the primary
tumour surgery specimen. Of 50 patients, material from before
and after the up-front FE120C courses was available. As a result
of technical problems (sections were not sufficiently adherent
to glass slides), less than 50 sample pairs were stained with
assessable results for Bcl-2 and ER. These data are summarized in
Table 2.
Bcl-2 was assessed in 43 sample pairs pre- and postchemother-
apy and Bcl-2 status remained the same in 24 (56%). In 10 patients,
Bcl-2 was negative in the prechemotherapy biopsy and positive in
the postchemotherapy resection specimen. In nine cases, Bcl-2 was
positive before chemotherapy and negative after. The difference in
Bcl-2 expression level before and after chemotherapy exposure was
not statistically significant.
ER was assessed in 49 pre- and postchemotherapy sample pairs
and remained the same in 35 (71%). In seven patients, ER was
negative in the prechemotherapy biopsy and positive in the
postchemotherapy resection specimen. In seven cases, ER was
positive before chemotherapy and negative after. The difference in
ER expression level before and after chemotherapy exposure was
not statistically significant.
HER2 was assessed in 50 pre- and postchemotherapy sample pairs
and remained the same in 47 (94%). In one patient, HER2 was
negative in the prechemotherapy biopsy and positive in the
postchemotherapy resection specimen. In two cases, HER2 was
positive before chemotherapy and negative after. The difference in
HER2 expression level before and after chemotherapy exposure
was not statistically significant.
P53 was assessed in 50 pre- and postchemotherapy sample pairs
and remained the same in 39 (78%). In six patients, P53 was
negative in the prechemotherapy biopsy and positive in the
postchemotherapy resection specimen. In five cases, P53 was
positive before chemotherapy and negative after. The difference in
P53 expression level before and after chemotherapy exposure was
not statistically significant.
Ki-67 was assessed in 50 pre- and postchemotherapy sample
pairs and remained the same in 31 (62%). Ki-67 count was high in
20 patients (40%) before treatment and in nine (18%) after. In four
patients, Ki-67 was low in the prechemotherapy biopsy and high in
the postchemotherapy resection specimen. In 15 cases, Ki-67 was
high before chemotherapy and low after. The mean proliferating
fraction was 38 per 200 before and 22 per 200 after chemotherapy
exposure as counted in 50 pairs of tumour samples. This difference
was statistically significant (P¼0.000053; two-sided t-test for
paired samples).
Correlating tumour characteristics with response
to FE120C
Prechemotherapy patient and tumour characteristics were tested
for correlation with integrated histopathological and clinical
tumour response. The tumour diameter at diagnosis was correlated
inversely with response (r¼ 0.27; P¼0.017), as was ER
expression (r¼ 0.40; P¼0.003). P53 expression was positively
correlated (r¼0.28; P¼0.046) with response.
The integrated response score was dichotomised as I–III or IV–
VII and crosstabulated vs all markers as positive or negative. Of 19
ER-negative tumours; six (32%) were in the best-response group vs
two (6%) out of 34 ER-positive tumours (P¼0.02; Fisher’s exact).
P53-positive tumours were more frequently in the best-response
group (6 of 22; 27%) than P53-negative tumours (two of 31; 6%)
(P¼0.05). Tumours with a high Ki-67 count (P¼0.02) were more
likely to have a better response (seven of 24; 29%) than low Ki-67
tumours (one of 29; 3%).
Bcl-2 and HER2 expression were not correlated with response to
FE120C. Table 3 gives significance of associations between marker
expression and all three response scores.
In a binary logistic regression model comprising all tested
markers as covariates and the integrated response score as a
IV. Histopathological changes in a macroscopic residual tumour mass and
a clinical complete or partial remission (pHRTM and cCR/cPR; n=39).
V. A clinical complete or partial remission but no pathological response (pNR
and cCR/cPR; n=19).
VI. Histopathological changes in a macroscopic residual tumour mass and
clinically stable disease (pHRTM and cSD; n=7).
VII. No pathological response and clinically stable disease (pNR and cSD; n=10).
Table 2 IHC results of five markers in sample pairs taken prior to and after FE120C neoadjuvant
treatment
Unchanged
N Pos Neg Pos-Neg Neg-Pos P-value
Bcl-2 43 16 8 9 10 NS
ER 49 25 10 7 7 NS
HER2 50 12 35 2 1 NS
P53 50 15 24 5 6 NS
High Low High-Low Low-High P-value
Ki-67 50 5 26 15 4 0.019
Unchanged=status remains unchanged after chemotherapy exposure. Pos=marker status is positive (>10%
staining cells). Neg=marker status is negative (0–10% staining cells). Pos-Neg (v.v.)=marker status changed
from positive to negative after chemotherapy exposure (v.v.). P-value=significance of changes in marker
expression after chemotherapy was tested with McNemar’s test.
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score was independently associated with response (P¼0.04).
Response to FE120C and survival
There was no association between response of the primary tumour
and OS. No statistically significant differences of OS between the
patient subgroups were found with either definition of response.
Log-rank analysis (Table 4) did show significant association of
DFS and response, but only if the integrated response score was
used (P¼0.04). The integrated response score did, however, not
predict a trend of increased DFS with increasing response (P¼0.9;
Cox regression): group III patients (pMRD and cPR/cSD) had the
longest DFS, whereas group I patients (pCR) relapsed relatively
fast. Patients with cCR (n¼15) had a 5-year OS of 60%. This was
not significantly different from non-cCR patients (n¼82) who
had a 5-year OS of 57% (P¼0.44). The 5-year DFS rates
(cCR¼60%; non-cCR¼41%) were also not significantly different
(P¼0.38).
The outcome in patients with any histopathological sign of
response (pCR, pMRD or pHRTM; n¼60) was equal to that in
patients with no signs of response (pNR; n¼29) in terms of 5-year
OS (59 and 54%, respectively; P¼0.97) and 5-year DFS (43 and
48%, respectively; P¼0.59).
Unexpectedly, patients with pCR (n¼3) had a relatively poor
outcome as two patients relapsed and died within 18 months
and the third was alive with a recurrence at the time of last follow-
up, 5.4 years after treatment. There was no association between
the expression of any of the IHC-determined markers and OS
or DFS.
Table 3 Significance levels (Fisher’s exact test; P-values) of association between IHC-detected marker expression (sample before
FE120C) and response by clinical, pathological and integrated assessment, all dichotomised and thus crosstabulated
Clinical cCR vs non-cCR Pathological Any vs none Combination I–III vs IV–VII
ER (n=53) 0.73 0.04* 0.02*
Positive 34 Any 18; None 16 I–III 2; IV–VII 32
Negative 19 Any 16; None 3 I–III 6; IV–VII 13
P53 (n=53) 0.07 0.04* 0.05*
Positive 22 Any 18; None 4 I–III 6; IV–VII 16
Negative 31 Any 16; None 15 I–III 2; IV–VII 29
Ki-67 (n=53) 0.03* 0.78 0.02*
High 24 CR 8; non-CR 16 I–III 7; IV–VII 17
Low 29 CR 2; non-CR 27 I–III 1; IV–VII 28
Bcl-2 (n=49) 0.24 1.0 1.0
HER2 (n=53) 0.25 0.76 1.0
*Association is statistically significant at the 0.05 level.
Table 4 (A) OS (P=0.1; log-rank statistics) and (B) DFS (P=0.04; log-rank statistics) for patient subgroups, by
integrated pathological and clinical tumour response
Integrated clinical and
pathological response N
No. of
patients
a
5-years
OS (%)
Median OS
in years (95% CI)
A, OS
I. pCR 3 2 33 1.5 (0.9–2.1)
II. pMRD and cCR 4 3 25 3.4 (0.6–6.2)
III. pMRD and cPR/cSD 7 1 100 7.3 (7.1–7.6)
IV. pHRTM and cCR/cPR 39 20 61 6.5 (4.7–8.2)
V. pNR and cCR/cPR 19 10 58 5.6 (ND)
VI. pHRTM and cSD 7 5 43 3.1 (0–6.6)
VII. pNR and cSD 10 5 47 4.3 (ND)
Integrated clinical and
pathological response N
No. of
patients
b
5-years
OS (%)
Median OS
in years (95% CI)
B, DFS
I. pCR 3 3 33 1.3 (0.7–2.0)
II. pMRD and cCR 4 3 25 1.7 (0.3–3.1)
III. pMRD and cPR/cSD 7 1 86 ND (ND)
IV. pHRTM and cCR/cPR 39 25 44 4.3 (3.3–5.3)
V. pNR and cCR/cPR 19 11 47 3.7 (0–7.6)
VI. pHRTM and cSD 7 6 14 3.0 (0–9.0)
VII. pNR and cSD 10 5 50 3.9 (ND)
aNumber of patients who died during follow-up.
bNumber of patients with an event during follow-up (death or recurrent disease).
ND=could not be determined.
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In a well-defined series of breast cancer patients (Rodenhuis
et al, 1998), we have studied chemotherapy-induced changes
of tumour phenotype. The overall aim of the study was to
provide a better insight into breast cancer response to chemo-
therapy.
To quantify tumour response, we used both the palpated tumour
sizes before and after chemotherapy and the residual tumour
volume in the surgical specimen. Although clinical response is
clearly correlated to findings at histopathological examination, it
does not appear to be an adequate parameter to use for assessment
of therapeutic success. It has been demonstrated before that
concordance between clinical and pathological findings in breast
cancer patients treated with primary chemotherapy is moderate at
best (Smith et al, 1995; Chollet et al, 1997). Our results show that
measurement by palpation overestimates the number of complete
remissions and underestimates the number of nonresponders, as
compared to histological assessment of tumour regression
(Table 1). We therefore used an additional scale for tumour
response, integrating both reduction in tumour size and histo-
pathologic changes.
We show that the expression of most of the tested markers
does not change after FE120C treatment (Table 2). Schneider
et al (2000) studied the expression of several markers in 48 pre-
and postchemotherapy breast carcinoma samples and reached
the same conclusion. In earlier publications, histological tumour
parameters were also determined before and after chemotherapy,
and were also found to remain largely unchanged (Frierson Jr
and Fechner, 1994; Sharkey et al, 1996). This implies that
these markers can be determined reliably in the prechemotherapy
biopsy as well as in the postchemotherapy surgical specimen. With
the increasing use of preoperative chemotherapy and with the
growing insight into molecular markers, this is an important
finding.
The only marker that was expressed differently in pre- vs
postchemotherapy samples was Ki-67, representing the proliferat-
ing fraction of the tumour. This finding is in line with studies
showing that doxorubicin treatment results in a significant
decrease of the mitotic activity (Honkoop et al, 1997) and of the
number of Ki-67-positive cells (Linn et al, 1997; Schneider et al,
2000). Decrease of Ki-67 expression is not only a monitor of
response to treatment, but our data also identify Ki-67 as an
independent predictor of response to anthracycline-based che-
motherapy. In a comparable study, involving 82 patients from two
separate doxorubicin-based neoadjuvant chemotherapy trials,
tumours with a high mitotic count had significantly more
responses than less proliferating tumours (Wang et al, 2002).
Probably a proliferating state renders tumour cells more sensitive
to chemotherapy: structural damage during DNA synthesis
induced by anthracycline exposure decreases the viability of newly
formed cancer cells (Collecchi et al, 1998; Billgren et al, 1999;
Makris et al, 1999).
In line with reports by others (MacGrogan et al, 1996; Kuerer
et al, 1999), our data also indicate that ER status is a marker of
chemosensitivity in breast cancer. Apparently – although func-
tionally unexplained – ER-negative breast carcinomas are more
sensitive to anthracycline-based chemotherapy.
With respect to HER2, a recent review of the published data
on both adjuvant and neoadjuvant chemotherapy concludes
that there is insufficient evidence to use HER2 expression
as a predictive factor in breast cancer, as many of the reviewed
studies present conflicting data (Hamilton and Piccart, 2000).
Our results also reject HER2 status as a predictive marker of
response to epirubicin treatment. Studies comparable to
ours – comprising a total of 429 patients, in whom the response
of the primary tumour to treatment with anthracyclines was
measured – have reached the same conclusions (MacGrogan
et al, 1996; Niskanen et al, 1997; Vargas-Roig et al, 1999; Vincent-
Salomon et al, 2000). In contrast, Colleoni et al (1999) report
that, in 40 patients, HER2-positive tumours (n¼5) had a
significantly increased response rate to neoadjuvant treatment
with doxorubicin.
The observed correlation between elevated P53 protein levels
and increased chemosensitivity was unexpected, although reported
in one earlier publication (Colleoni et al, 1999). It opposes the
generally accepted view that dysfunctional P53 causes resistance to
anthracyclines, as the result of a lacking DNA integrity check
(Lowe et al, 1993).
The relatively high dose of epirubicin (120mgm
 2) employed in
these patients may have an additional effect to a lower – and more
widely used – dosage of 60–90mgm
 2. Possibly, the DNA damage
that is initially tolerated with lacking P53 causes decreased viability
during subsequent tumour proliferation. In contrast, intact P53
induces apoptosis, or the DNA repair mechanism rescues cancer
cell viability.
It may also be that specific mutations necessary to
induce anthracycline resistance, described by Aas (Aas
et al, 1996), were relatively under-represented in our population.
Alternatively, a correlation between elevated P53 levels and
high proliferation index, as was previously reported (Allred et al,
1993), would have explained the apparent sensitivity of P53
positive tumours in our series. We did however find no such
association.
Another unexpected finding was that response to chemotherapy
was not predictive of outcome. Neither the clinical or pathological,
nor the additional integrated response score was predictive of
outcome. The response of a tumour is often used as a measure of
its chemosensitivity. If the response reflects the chemosensitivity
of all tumour cells – disseminated or locoregional – it would be
expected that response be positively correlated with outcome.
Results of the NSABP trial B-18, evaluating the merits of neo-
adjuvant chemotherapy for the treatment of stage I and II breast
cancer, support this.
In our patients no clinical evidence of distant dissemination
was found preoperatively. It is however likely that in a relatively
large percentage of this selected population, which had extensive
lymph node involvement, subclinical metastases were present.
It may be that patients’ OS and DFS were not so much determined
by the extent of cell kill induced by chemotherapy. Alternatively,
the remaining disseminated and chemoresistant tumour
cells, irrespective of their numbers, may have been the most
important determinant of outcome. In agreement with this
explanation is the recently published study by Gajdos
et al presenting a retrospective analysis of 144 locally advanced
breast cancer patients who had been treated with neo-
adjuvant chemotherapy. The authors found no associat-
ion between the clinical and pathological response and out-
come. However, distant DFS and OS were significantly related
to the number of tumour-positive axillary lymph nodes,
hinting at a role for tumour cell dissemination independent
of primary tumour sensitivity to chemotherapy (Gajdos et al,
2002).
The results of this study underline the inadequacy of palpated
tumour size as a parameter of breast cancer regression upon
cytotoxic treatment. We further show that exposure to anthracy-
cline-based chemotherapy does not result in significant changes of
the expression of several possibly predictive markers. Only the rate
of proliferation decreased markedly. For a clinical model predict-
ing breast cancer response to anthracycline-based chemotherapy,
ER status and Ki-67 count are probably the most useful of the
tested markers. However, in this study, response was not
associated with outcome, nor was expression of any of the
molecular markers.
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